miR-135a-5p mediates memory and synaptic impairments via the Rock2/Adducin1 signaling pathway in a mouse model of Alzheimer’s disease
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Small extracellular vesicles containing miR-486-5p promote angiogenesis after myocardial infarction in mice and nonhuman primates
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Decreased miR-214-3p activates NF-κB pathway and aggravates osteoarthritis progression
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome
Papers of interest to society members in the field of oligonucleotide therapeutics. Antisense, aptamers, lncRNA, siRNA, splice modulation and ribozymes.
Phase III Trial of ASO Therapy for the Treatment of Huntington’s Disease Halted
Recently, people who have been impacted by Huntington’s disease, their families, and the OTS community were disappointed to learn that the GENERATION HD1 Phase III study of Tominersen was halted based on the recommendation of an unblinded Independent Data Monitoring Committee. Although not based ...
Interview with Mark Behlke,MD, PhD
Mark Behlke, MD, PhD Chief Scientific Officer Integrated DNA Technologies, Inc. How did you become interested in the field of oligonucleotides? I had always thought that I would pursue a career in academic medicine, but in the Fall of 1995, I was visiting my ...
siRNA: From a Powerful Research Tool to Potent Therapeutic Modality
Earlier this year we celebrated the 20th Anniversary of RNA Interference in Mammalian Cells. In this article, we are going to discuss small interfering RNA (siRNA), a key mechanism that induces gene silencing in the RNAi pathway. siRNAs are highly specific, making them a ...
